Terms: = Leukemia AND CD52, CDW52, EDDM5
334 results:
1. Maintenance therapy for chronic lymphocytic leukaemia.
Lee CH; Wu YY; Huang TC; Lin C; Zou YF; Cheng JC; Chen PH; Jhou HJ; Ho CL
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD013474. PubMed ID: 38174814
[TBL] [Abstract] [Full Text] [Related]
2. cd52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D
Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535
[TBL] [Abstract] [Full Text] [Related]
3. [Chronic neutrophilic leukemia/chronic eosinophilic leukemia].
Kawashima I; Kirito K
Rinsho Ketsueki; 2023; 64(10):1326-1334. PubMed ID: 37914248
[TBL] [Abstract] [Full Text] [Related]
4. Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic leukemia.
Chiesa R; Georgiadis C; Syed F; Zhan H; Etuk A; Gkazi SA; Preece R; Ottaviano G; Braybrook T; Chu J; Kubat A; Adams S; Thomas R; Gilmour K; O'Connor D; Vora A; Qasim W;
N Engl J Med; 2023 Sep; 389(10):899-910. PubMed ID: 37314354
[TBL] [Abstract] [Full Text] [Related]
5. Targeted Large-Volume Lymphocyte Removal Using Magnetic Nanoparticles in Blood Samples of Patients with Chronic Lymphocytic leukemia: A Proof-of-Concept Study.
Janker S; Doswald S; Schimmer RR; Schanz U; Stark WJ; Schläpfer M; Beck-Schimmer B
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108680
[TBL] [Abstract] [Full Text] [Related]
6. T-Cell Prolymphocytic leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases.
Hu Z; Medeiros LJ; Xu M; Yuan J; Peker D; Shao L; Tang Z; Mai B; Thakral B; Rios A; Hu S; Wang W
Am J Clin Pathol; 2023 Apr; 159(4):325-336. PubMed ID: 36883805
[TBL] [Abstract] [Full Text] [Related]
7. Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.
Ivanov D; Milosevic Feenstra JD; Sadovnik I; Herrmann H; Peter B; Willmann M; Greiner G; Slavnitsch K; Hadzijusufovic E; Rülicke T; Dahlhoff M; Hoermann G; Machherndl-Spandl S; Eisenwort G; Fillitz M; Sliwa T; Krauth MT; Bettelheim P; Sperr WR; Koller E; Pfeilstöcker M; Gisslinger H; Keil F; Kralovics R; Valent P
Am J Hematol; 2023 May; 98(5):770-783. PubMed ID: 36814396
[TBL] [Abstract] [Full Text] [Related]
8. Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia.
Li K; Du Y; Cai Y; Liu W; Lv Y; Huang B; Zhang L; Wang Z; Liu P; Sun Q; Li N; Zhu M; Bosco B; Li L; Wu W; Wu L; Li J; Wang Q; Hong M; Qian S
Leukemia; 2023 Feb; 37(2):308-325. PubMed ID: 36543880
[TBL] [Abstract] [Full Text] [Related]
9. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia.
Ottaviano G; Georgiadis C; Gkazi SA; Syed F; Zhan H; Etuk A; Preece R; Chu J; Kubat A; Adams S; Veys P; Vora A; Rao K; Qasim W;
Sci Transl Med; 2022 Oct; 14(668):eabq3010. PubMed ID: 36288281
[TBL] [Abstract] [Full Text] [Related]
10. Subclones of bone marrow CD34
Jia R; Ji M; Li G; Xia Y; Guo S; Li P; Sun Y; Lu F; Zhang J; Zang S; Yan S; Ye J; Xue F; Ma D; Sun T; Ji C
Cancer; 2022 Nov; 128(22):3929-3942. PubMed ID: 36197314
[TBL] [Abstract] [Full Text] [Related]
11. Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study.
Ma S; Rosen ST; Winqvist M; Frankfurt O; Winter JN; Gordon L; Helenowski I; Zhang H; Kreutzer J; Sönnert-Husa S; Österborg A; Lundin J
Leuk Res; 2022 Nov; 122():106945. PubMed ID: 36115087
[TBL] [Abstract] [Full Text] [Related]
12. [Preparation of cd52-targeted chimeric antigen receptor-modified T cells and their anti-leukemia effects].
Liu Y; Liu Y; Tang KJ; Chen ZQ; Mou JL; Xu YX; Xing HY; Tian Z; Rao Q; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):279-286. PubMed ID: 35680625
[No Abstract] [Full Text] [Related]
13. [Comparison of the characteristics of NK cells after two different methods of expansion and observation of the clinical efficacy in patients who relapsed post allogeneic hematopoietic stem cell transplantation].
Cao XH; Wang ZD; Sun YQ; Kong J; Lu SY; Tang FF; Zhang YY; Wang JZ; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ; Zhao XY
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):400-407. PubMed ID: 35680598
[No Abstract] [Full Text] [Related]
14. Monoclonal antibodies for the treatment of acute lymphocytic leukemia: A literature review.
Pourmontaseri H; Habibzadeh N; Entezari S; Samadian F; Kiyani S; Taheri M; Ahmadi A; Fallahi MS; Sheikhzadeh F; Ansari A; Tamimi A; Deravi N
Hum Antibodies; 2022; 30(3):117-130. PubMed ID: 35662114
[TBL] [Abstract] [Full Text] [Related]
15. An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes.
Chen MM; Roufosse F; Wang SA; Verstovsek S; Durrani SR; Rothenberg ME; Pongdee T; Butterfield J; Lax T; Wechsler ME; Stein ML; Ogbogu PU; Kahwash BM; Mathur SK; Simon D; Akuthota P; Holland N; Wetzler L; Ware JM; Guo C; Fay MP; Khoury P; Klion AD; Bochner BS
J Allergy Clin Immunol Pract; 2022 May; 10(5):1217-1228.e3. PubMed ID: 35181548
[TBL] [Abstract] [Full Text] [Related]
16. Alemtuzumab clearance, lymphocyte count, and T-cell chimerism after hematopoietic stem cell transplant in sickle cell disease.
Furstenau D; Peer CJ; Hughes TE; Uchida N; Tisdale J; Hall OM; Figg WD; Hsieh M
Pharmacotherapy; 2022 Jan; 42(1):14-22. PubMed ID: 34669981
[TBL] [Abstract] [Full Text] [Related]
17. cd52/GPI- T-Cells Are Enriched for Alloreactive Specificity and Predict Acute Graft-Versus-Host-Disease After Stem Cell Transplantation.
Kinsella FA; Inman CF; Croft W; Zuo J; Pearce H; Barbieri S; Craddock C; Malladi R; Moss P
Transplant Cell Ther; 2021 Jun; 27(6):475.e1-475.e9. PubMed ID: 33863699
[TBL] [Abstract] [Full Text] [Related]
18. Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia.
Eisenwort G; Sadovnik I; Keller A; Ivanov D; Peter B; Berger D; Stefanzl G; Bauer K; Slavnitsch K; Greiner G; Gleixner KV; Sperr WR; Willmann M; Sill H; Bettelheim P; Geissler K; Deininger M; Rülicke T; Valent P
Leukemia; 2021 Nov; 35(11):3176-3187. PubMed ID: 33785864
[TBL] [Abstract] [Full Text] [Related]
19. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic leukemia.
Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
[TBL] [Abstract] [Full Text] [Related]
20. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
[TBL] [Abstract] [Full Text] [Related]
[Next]
